Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood

Blood

Volumn 93, Issue 9, 1999, Pages 3026-3032

  Chen, Honglin ^b   Smith, Paul ^b   Ambinder, Richard F ^b   Hayward, S Diane ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD23 ANTIGEN; COMPLEMENTARY DNA; MESSENGER RNA;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CARCINOGENESIS;

EID: 0033134768     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.9.3026     Document Type: Article

References (51)

1. Rickinson AB, Kieff E: Epstein-Barr virus, in Field BN, Knipe DM, Howley PM (eds): Fields Virology, vol 2 (ed 3). New York, NY, Raven, 1996, p 2397
2. Niedobitek G, Young LS: Epstein-Barr virus persistence and virus-associated tumor. Lancet 343:333, 1994
3. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA: Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5:173, 1996
4. Yao QY, Rickinson AB, Epstein A: A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35:35, 1985
5. Kieff E: Epstein-Barr virus and its replication, in Field BN, Knipe DM, Howley PM (eds): Fields Virology, vol 2 (ed 3). New York, NY, Raven, 1996, p 2343
6. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB: Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66:122, 1992
7. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J 6:2743, 1987
8. Brooks LA, Lear AL, Young LS, Rickinson AB: Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 67:3182, 1993
9. Busson P, McCoy R, Sadler R, Gilligan K, Tursz T, Raab-Traub N: Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 66:3257, 1992
10. Hitt MM, Allday M, Hara T, Karran L, Jones MD, Busson P, Tursz T, Ernberg I, Griffin B: EBV gene expression in an NPC-related tumor. EMBO J 8:2639, 1989
11. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS: Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339, 1993
12. Chen CL, Sadler RH, Walling DM, Su IJ, Hsieh HC, Raab-Traub N: Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 67:6303, 1993
13. Minarovits J, Hu LF, Imai S, Harabuchi Y, Kataura A, Minarovits-Kormuta S, Osato T, Klein G: Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 75:77, 1994
14. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176:157, 1992
15. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ: Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176:169, 1992
16. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG: Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685, 1995
17. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG: Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94:12616, 1997
18. Smith PR, Griffin BE: Transcription of the Epstein-Barr virus gene, EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells. J Virol 66:706, 1992
19. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J: Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70:623, 1996
20. Schaefer BC, Strominger JL, Speck SH: Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA 92:10565, 1995
21. Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson A, Kieff E: Restricted EBV protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 88:6343, 1991
22. Schaefer BC, Woisetschlaeger M, Strominger JL, Speck SH: Exclusive expression of EBV nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promotors used in latently infected lymphocytes. Proc Natl Acad Sci USA 88:6550, 1991
23. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA: A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593, 1995
24. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB: Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 43:67, 1989
25. Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I: Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693, 1988
26. Decker LL, Klaman LD, Thorley-Lawson DA: Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol 70:3286, 1996
27. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA: Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882, 1997
28. Qu L, Rowe DT: Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66:3715, 1992
29. Tierney RJ, Steven N, Young LS, Rickinson AB: Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374, 1994
30. Chen F, Zou J-Z, di Renzo L, Winberg G, Hu L-F, Klein E, Klein G, Ernberg I: A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69:3752, 1995
31. Chen H-L, Lung MML, Sham JST, Choy DTK, Griffin BE, Ng MH: Transcription of BamHI-A. region of the EBV genome in NPC tissues and B cells. Virology 191:193, 1992
32. Gilligan K, Sato H, Rajadural P, Busson P, Young L, Rickinson A, Tursz T, Raab-Traub N: Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol 64:4948, 1990
33. Fries KL, Sculley TB, Webster-Cyriaque J, Rajadurai P, Sadler RH, Raab-Traub N: Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol 71:2765, 1997
34. Gilligan KJ, Rajadurai P, Lin JC, Busson P, Abdel-Hamid M, Prasad U, Tursz T, Raab-Traub N: Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: Evidence for viral protein expressed in vivo. J Virol 65:6252, 1991
35. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue. Blood 91:1373, 1998
36. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: Unique viral latency in the tumor cells. Br J Cancer 74:625, 1996
37. Webster-Cyriaque J, Raab-Traub N: Transcription of Epstein-Barr virus latent cycle genes in oral hairy leukoplakia. Virology 248:53, 1998
38. Chiang AK, Tao Q, Srivastava G, Ho FC: Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68:285, 1996
39. Sadler RH, Raab-Traub N: Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol 69:1132, 1995
40. Smith PR, Gao Y, Karran L, Jones MD, Snudden D, Griffin BE: Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J Virol 67:3217, 1993
41. Robertson ES, Tomkinson B, Kieff E: An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARFO transforms B lymphocytes in vitro. J Virol 68:1449, 1994
42. Denhardt DT: A membrane-filter technique for the detection of complementary DNA. Biochem Biophys Res Commun 23:641, 1966
43. Rochford R, Mosier DE: Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes. J Virol 69:150, 1995
44. Farrell PJ: Epstein-Barr Virus CB95-8 strain, in O'Brien SJ (ed): Genetic Maps (ed 5). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1990, p 102
45. Parker BD, Bankier A, Satchwell S, Barrell B, Farrell PJ: Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology 179:339, 1990
46. Kikutani H, Inui S, Sato R, Barsumian E, Owaki H, Yamasaki K, Kaisho T, Uchibayashi N, Hardy RR, Hirano T, Tsunasawa S, Sakiyama F, Suemura M, Kishimoto T: Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell 47:657, 1996
47. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15:405, 1997
48. Burrows SR, Gardner J, Khanna R, Steward T, Moss DJ, Rodda S, Suhrbier A: Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 75:2489, 1994
49. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors, Cell 76:263, 1994
50. Fruehling S, Longnecker R: The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241, 1997
51. Miller CL, Lee JH, Kieff E, Longnecker R: An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 91:772, 1994